Pooled Analysis of Real-World Evidence Supports Anti-CGRP mAbs and OnabotulinumtoxinA Combined Trial in Chronic Migraine

Pooled Analysis of Real-World Evidence Supports Anti-CGRP mAbs and OnabotulinumtoxinA Combined Trial in Chronic Migraine

OnabotulinumtoxinA, targeting the CGRP machinery, has been approved for the last two decades for chronic migraine prevention. The recently approved monoclonal antibodies (mAbs) directed towards the calcitonin gene-related peptide (CGRP) pathway open a new age for chronic migraine control. However, s...

Full description

Bibliographic Details
Main Authors: Damiana Scuteri, Paolo Tonin, Pierluigi Nicotera, Marilù Vulnera, Giuseppina Cristina Altieri, Assunta Tarsitano, Giacinto Bagetta, Maria Tiziana Corasaniti
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Toxins
Subjects:
onabotulinumtoxinA
migraine
anti-CGRP monoclonal antibodies
PRISMA 2020
pooled analysis
Online Access:https://www.mdpi.com/2072-6651/14/8/529

Similar Items

Similar Items